Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Keith T FlahertyRobert J GrayHelen X ChenShuli LiLisa Meier McShaneDavid R PattonStanley R HamiltonP Mickey WilliamsA John IafrateJeffrey SklarEdith P MitchellLyndsay N HarrisNaoko TakebeDavid J SimsBrent CoffeyTony FuMark J RoutbortJames A ZwiebelLawrence V RubinsteinRichard F LittleCarlos L ArteagaRobert ComisJeffrey S AbramsPeter J O'DwyerBarbara A Conleynull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
We demonstrated feasibility of screening large numbers of patients at numerous accruing sites in a complex trial to test investigational therapies for moderately frequent molecular targets. Co-occurring resistance mutations were common and endorse investigation of combination targeted-therapy regimens.